Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
NOAEL / key findings
No NOAEL; in vitro alloreactivity against HLA-A*02:05 (contraindication); cross-reactivity to MAGE-A8/MAGE-B2 (cancer/germline-restricted)
“An alloreactivity screen against a panel of cells expressing a range of HLA alleles indicated in vitro alloreactivity against HLA-A*02:05. Therefore, afamitresgene autoleucel is contraindicated for adults who are heterozygous or homozygous for HLA-A*02:05P.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗